Blacksmith Medicines, a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases, has secured seed funding and entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing Blacksmith investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics.

The Blacksmith metalloenzyme platform is a unique drug discovery engine purpose-built to target the largest and most diverse group of enzymes in the human genome.